Immunohistochemical study of the expression of matrix metalloproteinase-9 in skin lesions of mycosis fungoides

American Journal of Dermatopathology

Volumn 32, Issue 2, 2010, Pages 162-169

  Rasheed, Hoda ^a   Tolba Fawzi, Marwa Mohsen ^a   Abdel Halim, Mona R E ^a   Eissa, Amal M ^a   Mohammed Salem, Nahla ^b   Mahfouz, Soheir ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b MAFRAQ HOSPITAL   (United Arab Emirates)

Author keywords

Matrix metalloproteinases; MMP 9; Mycosis fungoides; Tumor progression

Indexed keywords

GELATINASE B;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MYCOSIS FUNGOIDES; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYCOSIS FUNGOIDES; SEVERITY OF ILLNESS INDEX; SKIN; SKIN NEOPLASMS; YOUNG ADULT;

EID: 77949974222     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e3181b72678     Document Type: Article

References (36)

1. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol. 2001;17:463-516.
2. Nagase H, Woessner JF. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491-21492.
3. Kahari VM, Saarialho-Kere UK. Metalloproteinases in the skin. Exp Dermatol. 1999;6:199-214.
4. Loukopoulos BA, Mungall RC, Straw JR, et al. Matrix metalloproteinase-2 and -9 involvement in canine tumours. Vet Pathol. 2003;40:382-394.
5. Westermarck J, Kahari V. Regulation of matrix metalloproteinase expression in tumour invasion. FASEB J. 1999;13:781-792.
6. Ohtani H, Motohashi H, Sato H. Dual over-expression pattern of membrane-type metalloproteinase-1 in cancer and stromal cells in human gastrointestinal carcinoma revealed by in situ hybridization and immunoelectron microscopy. Int J Cancer. 1996;68:565-570.
7. Bernhard EJ, Gruber SB, Muschel RJ. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc Natl Acad Sci U S A. 1994;91:4293-4297.
8. Katayama A, Bandoh N, Kishibe K, et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumour metastases and prognosis. Clin Cancer Res. 2004;10:634-640.
9. Hartlapp I, Abe R, Ubina WR, et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J. 2001;15:2215-2224.
10. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphoma: a proposal from the cutaneous lymphoma study group of the European organization for research and treatment of cancer. Blood. 1997;90:354-371.
11. Mackie RM. Cutaneous lymphoma and lymphocytic infiltrates. In: Champion RH, Burton JL, Burns DA, et al, eds. Rook/Wilkinson/Ebling Textbook of Dermatology. 6th ed. Oxford, London, UK: Blackwell Science Ltd; 1998:2373-2375.
12. Diamandidou E, Cohen PR, Kurzrock R. Mycosis fungoides and Sezary syndrome. Blood. 1996;88:2385-2409.
13. Murphy GF, Schwarting R. Cutaneous lymphomas and leukemias. In: Elder DE, Elenitsas R, Johnson BL Jr, et al, eds. Lever,s Histopathology of the Skin. 9th ed. Philadelphia, PA: LippincottWilliams andWilkins; 2005: 950-954.
14. Vacca A, Moretti S, Ribatti D. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of the matrix metalloproteinases 2 and 9. Eur J Cancer. 1997;33:1685-1692.
15. Bunn P, Lamberg S. Report of the committee on staging and classification of cutaneous T-cell lymphoma. Cancer Treat Rep. 1979;63:725-728.
16. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374.
17. Baumgarter TA, Strong CH. Conducting and Reading Research in Health and Human Performance. 2nd ed. New York, NY: McGraw-Hill; 1998.
18. TorII A, Kodera Y, Mesaka K, et al. Plasma concentration of matrix metalloproteinase 9 in gastric cancer. Br J Surg. 1997;84:133-136.
19. Toshihiko I, Takehiko F, Makoto S, et al. Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients. Clin Cancer Res. 1999;5:149-153.
20. Schmalfeldt B, Prechtel D, Harting K, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001;7:2396-2404.
21. Durkan GC, Nut JE, Marsh C, et al. Alteration in urinary matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio predicts recurrence in nonmuscle-invasive bladder cancer. Clin Cancer Res. 2003;9:2576-2582.
22. Rocca GL, Minafra P, Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer. 2004;90:1414-1421.
23. Flavell JR, Baumforth KR, Williams DM, et al. Expression of the matrix metalloproteinase 9 in Hodgkin,s disease is independent of EBV status. Mol Pathol. 2000;53:145-149.
24. Kamiguti AS, Lee ES, Till KJ, et al. The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemia. Br J Haematol. 2004;125:128-140.
25. Vacca A, Ribatti D, Ria R, et al. Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev Immunol. 2000;7: 77-88.
26. John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumour metastasis. Pathol Oncol Res. 2001;7:14-23.
27. Johnatty RN, Taub DD, Reeder SP, et al. Cytokine and chemokine regulation of pro MMP-9 and TIMP-2 production by human peripheral blood lymphocytes. J Immunol. 1997;158:2327-2333.
28. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9:997-1010.
29. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non- Hodgkin,s lymphomas. Blood. 1999;94:2080-2089.
30. Aoudjit F, Potworowski EF, Yves SP. Bi-directional induction of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 during T lymphoma/endothelial cell contact: implication of ICAM-1. J Immunol. 1998;160:2967-2973.
31. Mazur G,Woźniak Z, Wróbel T, et al.Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res. 2004;10:34-36.
32. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumourigenesis. Cell. 1996;86:353-364.
33. Salven P, Lymboussaki A, Heikkila P, et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumours. Am J Pathol. 1998;153:103-108.
34. Kalebic T, Garbisa S, Glaser B, et al. Basement membrane collagen: degradation by migrating endothelial cells. Science. 1983;221:281-283.
35. Cornelius LA, Nehring LC, Harding E, et al. Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol. 1998;161: 6845-6852.
36. Zorina S, Galis Jaikirshan J, et al. Matrix metalloproteinases in vascular remodeling and atherogenesis. J Am Acad Dermatol. 2002;34: 368-374.